Fourtillan J B, Courtois P, Lefebvre M A, Girault J
Eur J Clin Pharmacol. 1981 Feb;19(3):193-6. doi: 10.1007/BF00561948.
The pharmacokinetics of timolol, after oral administration of single 20 mg doses to healthy subjects, has been studied using an original electron beam ionization GLC-mass spectrometry technique with computer -- controlled multiple ion detection. This method of mass fragmentography, tested with propranolol as an internal standard, permitted the measurement of timolol concentrations as low as 1 ng/ml with good precision and accuracy. It enabled the plasma level to be followed up to the twelfth hour after treatment. Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5--3h). The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml). The mean half-life of the terminal elimination phase was 2.62 +/- 0.17 h. Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123. This level paralleled the percentage of unaltered timolol excreted in urine 24 h after its administration.
对健康受试者单次口服20毫克剂量的噻吗洛尔后的药代动力学进行了研究,采用了一种原始的电子束电离气相色谱-质谱联用技术,并结合计算机控制的多离子检测。这种质量碎片分析法以普萘洛尔作为内标进行测试,能够精确测量低至1纳克/毫升的噻吗洛尔浓度。它能够追踪治疗后长达12小时的血浆水平。观察到生物利用度存在个体差异;在不同时间(0.5-3小时)达到的血浆峰值浓度(Cmax)为50至103纳克/毫升。12小时后的残留水平在受试者之间差异很大(0.8至7.2纳克/毫升)。终末消除相的平均半衰期为2.62±0.17小时。肾外消除(代谢和胆汁排泄)是主要的消除途径,肾清除率与全身清除率之比为0.123。这一水平与给药后24小时尿液中未改变的噻吗洛尔排泄百分比相当。